🌟 NurExone Expanding to US Financial Markets with OTCQB Listing Approval and DTC Eligibility 🌟 Shares trading under the symbol NRXBF. #USmarketaccess #biopharmaceutical #OTCQB #DTC #innovation https://lnkd.in/dz9xEM8G
NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
Biotechnology Research
Regenerate - Rewire - Recover
About us
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.
- Website
-
https://nurexone.com
External link for NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Haifa
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
Haifa, IL
Employees at NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90)
-
Yossi Mograbi
-
Lior Shaltiel, PhD
Chief Executive Officer at NurExone Biologic (TSXV:NRX)(OTCQB:NRXBF)(FSE:J90) | Senior Lecturer (of the practice) Head of the BioMed-MBA program at…
-
Kineret Taler
Preclinical Study Manager at NurExone Biologic
-
Eran Ovadya
Chief Financial Officer at NurExone Biologic Inc [TSXV:"NRX"] [OTCQB:"NRXBF"] [FRA/DEU/STU/MUN/BER/HAM:"J90"]
Updates
-
https://lnkd.in/daVfN-36 Gaining recognition as a leader in the field of exosomes for drug delivery! Lior Shaltiel, PhD has been invited to present at the prestigious Exosomes Europe conference in London this June on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach."
-
-
Analyst update following FY23 financials release! The company surpassed EPS estimates for FY23 and has met significant milestones since the beginning of 2024. Detailed insights in the full report. #AnalystUpdate #Regenerativemedicine
-
We’re #hiring. Know anyone who might be interested?
-
Analyst Theodore R. O’Neill of Litchfield Hills Research, LLC reiterates NurExone buy rating and CAD$4 price target. #InvestmentResearch #Biotech #Finance #MarketInsights
-
NurExone Reports Q4 2023 Financial Results & Company Update! 🌟 R&D focus in 2023 driving the introduction of #minimallyinvasive #regenerative #medicine! #NurExone #Biopharmaceutical #RegenerativeMedicine #Healthcare #Finance #Investment #FDA #Innovation #MedicalResearch https://lnkd.in/dNG_S8kg
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
globenewswire.com
-
https://lnkd.in/dh69jCE9 Thrilled to announce that the exercise of warrants has resulted in gross proceeds of approximately C$4 million for NurExone! With gratitude to our investors for their unwavering support, we look forward to leveraging these new funds to propel forward our development and commercial efforts. #BiotechInnovation #NerveRegeneration #MedicalBreakthroughs #InvestinginHealth #NurExoneBiologic
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
globenewswire.com
-
https://lnkd.in/dBjUPyRW Large scale preclinical testing to be performed on ExoPTEN.. A step closer to clinical trials and added hope for patients with acute spinal cord injuries.... #ExoTherapy #Nanodrugs #OrphanDrugs #Medicalinnovation
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
globenewswire.com
-
https://lnkd.in/d-_4yGPA Discover ExoPTEN, an innovative therapy being developed by NurExone Biologic to redefine treatment for Acute Spinal Injuries! A new article by NoCamels - Israeli Tech & Innovation News #ExoPTEN #SpinalInjuryTherapy #NurExoneBiologic #MedicalInnovation #Unlockinghope
Nasal Therapy That Could Help People With Spinal Injuries Walk Again
https://nocamels.com